The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.
 
Frederic Forget
Travel, Accommodations, Expenses - ipsen; Teva
 
Serafin Morales Murillo
No Relationships to Disclose
 
Nuhad K. Ibrahim
No Relationships to Disclose
 
Bernard Doger de Spéville Uribe
No Relationships to Disclose
 
Omkar Marathe
No Relationships to Disclose
 
Jean-Luc Re Canon
Honoraria - AstraZeneca/Daiichi Sankyo; Lilly; Seagen
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Lilly; Sanofi; Seagen
Research Funding - Bristol-Myers Squibb/Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Roche/Genentech
 
Pavani Chalasani
Consulting or Advisory Role - Atossa Genetics; bioTheranostics; Gilead Sciences; Lilly; OncoSec; Puma Biotechnology
Research Funding - Amgen (Inst); BioAtla (Inst); Carrick Therapeutics (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Radius Health (Inst); Ventana Medical Systems (Inst); Zentalis (Inst)
 
Konstantinos Papadimitriou
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Roche (Inst)
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Merck; Novartis; Roche
 
Mafalda Oliveira
Honoraria - AstraZeneca; Eisai Europe; Gilead Sciences; Lilly; Medscape; Pfizer; Roche; SeaGen
Consulting or Advisory Role - AstraZeneca; Cureo Science; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; iOne; ITeos Therapeutics; Lilly; MSD; Pfizer; Relay Therapeutics; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Eisai; Gilead Sciences; Pierre Fabre
(OPTIONAL) Uncompensated Relationships - Head of the SOLTI Breast Cancer Research Group
 
Elia Seguí
Honoraria - Daiichi Sankyo Europe GmbH; Eisai; Novartis; Pfizer
Consulting or Advisory Role - Pfizer; Seagen
Research Funding - Amgen Astellas BioPharma
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer
 
Frederic Triebel
Employment - Immutep
Stock and Other Ownership Interests - Immutep
Patents, Royalties, Other Intellectual Property - Being an inventor on patents on LAG-3 owned by Immutep SAS